

I N T H I S I S S U E

Personal Account of MDMA Research Subject <i>handyman@wla.com</i>	2	Phase 1 MDMA Research <i>Charles S. Grob, MD</i>
On MDMA Neurotoxicity <i>Rick Doblin</i>	4	Personal Account of MDMA Research Subject <i>Dianne</i>
MDMA : Healing Fears and Depression <i>Carolyn</i>	7	On MDMA Neurotoxicity <i>James P. O'Callaghan, Ph.D.</i>
University of New Mexico Update <i>Rick Strassman, MD</i>	8	LSD Update <i>Richard Jensen, Ph.D.</i>
Art Therapy and Psilocybin <i>Tamara D. Allen</i>	13	Psychedelic Nursing <i>Laura Berg</i>
Ketamine Research in Florida <i>Eli Kolp, MD</i>	14	Ketamine Research Update: Russia <i>Evgeny Krupitsky, MD, Ph.D.</i>
Clinical Research Update: Switzerland <i>Dr. Samuel Widmer</i>	15	Phase I Ibogaine Research <i>Deborah C. Mash, Ph.D.</i>
Spiritual Uses of MDMA in Traditional Religion <i>Nicholas Saunders</i>	16	Swiss Research With Psychedelics <i>Franz Vollenweider</i>
Youths and Entheogen Use <i>Andrei Foldes, with Amba Morton, Eric Johnson, et al.</i>	17	An Invitation to Entheological Dialogue <i>Rev. Mike Young</i>
Cannabis Patient Registry Update <i>Sylvia Thyssen</i>	23	Medical Marijuana Research Update <i>Rick Doblin</i>
Heffter Research Institute Update <i>Dr. David Nichols</i>	27	The Hofmann Report <i>Myron Stolaroff and Michael Gilbert</i>
Book Review of LSD: Still With Us After All These Years <i>By Neal M. Goldsmith, Ph.D.</i>	28	World Wide Web Psychedelic Research Bibliography <i>Eric Katt</i>
	29	MAOI Contraindications <i>Alfred Savinelli And John H. Halpern, M.D.</i>
	31	MAPS Forum
	32	MAPS Annual Report <i>Rick Doblin</i>
	33	Membership

Cover: "Ripple" – photos and digital assembly by a MAPS contributor.

"During the night, fog moves over the dunes. Morning breezes carve delicate shapes in the moist sand. The sun chases away the fog. The sand dries and these ephemeral creatures return to dust."

ISSN 1080-8981

MAPS (Multidisciplinary Association for Psychedelic Studies) is a membership-based organization working to assist psychedelic researchers around the world design, obtain governmental approval, fund, conduct and report on psychedelic research in humans. Founded in 1986, MAPS is an IRS approved 501 (c)(3) non-profit corporation funded by tax deductible donations. MAPS has previously funded basic scientific research into the safety of MDMA (3,4, methylenedioxymethamphetamine, *Ecstasy*) and has opened a Drug Master File for MDMA at the U.S. Food and Drug Administration. MAPS is now focused primarily on assisting scientists to conduct human studies to generate essential information about the risks and psychotherapeutic benefits of MDMA, other psychedelics, and marijuana, with the goal of eventually gaining government approval for their medical uses. Interested parties wishing to copy any portion of this newsletter are encouraged to do so and are kindly requested to credit MAPS including name and address. The MAPS newsletter is produced by a small group of dedicated volunteers. Your participation, financial or otherwise, is welcome. © 1995 Multidisciplinary Association for Psychedelic Studies, Inc. (MAPS) 1801 Tippah Avenue, Charlotte, NC 28205. Phone: (704) 358-9830. Fax: (704) 358-1650. Internet: rick@maps.org or sylvia@maps.org, and on Web: <http://www.maps.org>